Jeroen Eikenboom

15.0k total citations · 2 hit papers
250 papers, 8.1k citations indexed

About

Jeroen Eikenboom is a scholar working on Hematology, Genetics and Surgery. According to data from OpenAlex, Jeroen Eikenboom has authored 250 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Hematology, 47 papers in Genetics and 39 papers in Surgery. Recurrent topics in Jeroen Eikenboom's work include Platelet Disorders and Treatments (152 papers), Blood groups and transfusion (72 papers) and Hemophilia Treatment and Research (57 papers). Jeroen Eikenboom is often cited by papers focused on Platelet Disorders and Treatments (152 papers), Blood groups and transfusion (72 papers) and Hemophilia Treatment and Research (57 papers). Jeroen Eikenboom collaborates with scholars based in Netherlands, United Kingdom and Italy. Jeroen Eikenboom's co-authors include Frank W.G. Leebeek, Rogier M. Bertina, Johanna G. van der Bom, Frits R. Rosendaal, Pieter W. Kamphuisen, Giancarlo Castaman, Menno V. Huisman, Jaapjan D. Snoep, Karine M. Valentijn and Marcel M.C. Hovens and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jeroen Eikenboom

238 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Von Willebrand’s Disease

2016 365 citations Frank W.G. Leebeek, Jeroen Eikenboom profile →
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease

2021 285 citations Paula James, Jeroen Eikenboom et al. Blood Advances profile →

Peers

Countries citing papers authored by Jeroen Eikenboom

Since Specialization

Citations

This map shows the geographic impact of Jeroen Eikenboom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeroen Eikenboom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeroen Eikenboom more than expected).

Fields of papers citing papers by Jeroen Eikenboom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeroen Eikenboom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeroen Eikenboom. The network helps show where Jeroen Eikenboom may publish in the future.

Co-authorship network of co-authors of Jeroen Eikenboom

This figure shows the co-authorship network connecting the top 25 collaborators of Jeroen Eikenboom. A scholar is included among the top collaborators of Jeroen Eikenboom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeroen Eikenboom. Jeroen Eikenboom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs 2025 ·Blood Advances ·(unknown), (unknown), Richard Dirven, (unknown), Ruben Bierings, Caterina Casari, Robert A. Cordfunke, James E. Dahlman, (unknown), Jan W. Drijfhout, Frank W.G. Leebeek, L. Renee Ruhaak, Elisa Schrader Echeverri, Jan Voorberg, Bart J.M. van Vlijmen, Cécile V. Denis, Jeroen Eikenboom	6
2	Peri‐operative desmopressin combined with pharmacokinetic‐guided factor VIII concentrate in non‐severe haemophilia A patients 2024 ·Haemophilia ·(unknown), (unknown), Reinier M. van Hest, Karina Meijer, Britta A. P. Laros‐van Gorkom, Laurens Nieuwenhuizen, Jeroen Eikenboom, Floor Heubel-Moenen, (unknown), Michiel Coppens, Karin Fijnvandraat, M.H.E. Driessens, Suzanne Polinder, Marjon H. Cnossen, Frank W.G. Leebeek, Ron A. A. Mathôt, Marieke J. H. A. Kruip	0
3	Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease 2022 ·Blood Advances ·Ferdows Atiq, (unknown), (unknown), Johan Boender, (unknown), Waander L. van Heerde, (unknown), (unknown), (unknown), Joke de Meris, Saskia E.M. Schols, (unknown), Johanna G. van der Bom, Marjon H. Cnossen, Karina Meijer, Karin Fijnvandraat, Jeroen Eikenboom, Frank W.G. Leebeek	9
4	Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting 2022 ·Research and Practice in Thrombosis and Haemostasis ·(unknown), (unknown), Michiel Coppens, Samantha C. Gouw, Sara Boyce, Catherine Bagot, Erik A.M. Beckers, Paul Brons, Giancarlo Castaman, Jeroen Eikenboom, Shannon Jackson, Marieke J. H. A. Kruip, Frank W.G. Leebeek, Karina Meijer, Laurens Nieuwenhuizen, Ingrid Pabinger, Karin Fijnvandraat	7
5	Interaction of von Willebrand factor with blood cells in flow models: a systematic review 2022 ·Blood Advances ·(unknown), (unknown), Saskia E.M. Schols, Jeroen Eikenboom, Moniek P.M. de Maat	8
6	Clinical value of early viscoelastometric point‐of‐care testing during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands 2021 ·Acta Obstetricia Et Gynecologica Scandinavica ·(unknown), (unknown), Dacia D. C. A. Henriquez, Camila Caram‐Deelder, (unknown), Moniek P.M. de Maat, Johannes J. Duvekot, Jeroen Eikenboom, Kitty W.M. Bloemenkamp, J. M. M. van Lith, Thomas van den Akker, Johanna G. van der Bom	16
7	Hepatitis C virus in hemophilia: Health‐related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study 2021 ·Research and Practice in Thrombosis and Haemostasis ·(unknown), Samantha C. Gouw, Erna C. van Balen, (unknown), Erik A.M. Beckers, Johanna G. van der Bom, Michiel Coppens, Jeroen Eikenboom, Kathelijn Fischer, (unknown), Frank W.G. Leebeek, Frits R. Rosendaal, Saskia E.M. Schols, Cees Smit, Lize F. D. van Vulpen, Eveline P. Mauser‐Bunschoten	5
8	Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study 2021 ·Haemophilia ·(unknown), Erna C. van Balen, (unknown), Saskia E.M. Schols, Frank W.G. Leebeek, Jeroen Eikenboom, Michiel Coppens, Lize F. D. van Vulpen, Cees Smit, M.H.E. Driessens, Janjaap van der Net, Samantha C. Gouw, Kathelijn Fischer	13
9	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients 2020 ·Thrombosis and Haemostasis ·(unknown), (unknown), (unknown), Roger E. G. Schutgens, Britta A. P. Laros‐van Gorkom, Laurens Nieuwenhuizen, F.J.M. van der Meer, Karin Fijnvandraat, Paula F. Ypma, Moniek P.M. de Maat, Frank W.G. Leebeek, Karina Meijer, Jeroen Eikenboom, Ron A. A. Mathôt, Marjon H. Cnossen, (unknown)	5
10	Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease 2020 ·Journal of Thrombosis and Haemostasis ·(unknown), Mackenzie Bowman, Colleen Notley, (unknown), Patrícia Lima, Annika de Jong, Richard Dirven, Ester M. Weijers, David Lillicrap, Paula James, Jeroen Eikenboom	20
11	Comparison of thromboelastometry by ROTEM ^® Delta and ROTEM ^® Sigma in women with postpartum haemorrhage 2019 ·Scandinavian Journal of Clinical and Laboratory Investigation ·(unknown), Thomas van den Akker, Camila Caram‐Deelder, Dacia D. C. A. Henriquez, Kitty W.M. Bloemenkamp, Jeroen Eikenboom, Johanna G. van der Bom, Moniek P.M. de Maat	38
12	Variability of von Willebrand factor‐related parameters in endothelial colony forming cells 2019 ·Journal of Thrombosis and Haemostasis ·Annika de Jong, Ester M. Weijers, Richard Dirven, (unknown), (unknown), Jeroen Eikenboom	17
13	Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study 2018 ·Blood Advances ·(unknown), Thomas van den Akker, Camila Caram‐Deelder, Dacia D. C. A. Henriquez, Kitty W.M. Bloemenkamp, Moniek P.M. de Maat, Jos van Roosmalen, Joost J. Zwart, Jeroen Eikenboom, Johanna G. van der Bom	37
14	Correction of a dominant‐negative von Willebrand factor multimerization defect by small interfering RNA‐mediated allele‐specific inhibition of mutant von Willebrand factor 2018 ·Journal of Thrombosis and Haemostasis ·Annika de Jong, Richard Dirven, (unknown), (unknown), Bart J.M. van Vlijmen, Jeroen Eikenboom	19
15	The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study 2017 ·PLoS ONE ·(unknown), Dacia D. C. A. Henriquez, Thomas van den Akker, Camila Caram‐Deelder, (unknown), Joost J. Zwart, Jos van Roosmalen, Jeroen Eikenboom, Kitty W.M. Bloemenkamp, Johanna G. van der Bom, (unknown)	33
16	Time-Dependent Effects of Aspirin on Blood Pressure and Morning Platelet Reactivity 2015 ·Hypertension ·Tobias Bonten, Jaapjan D. Snoep, Willem JJ Assendelft, Jaap Jan Zwaginga, Jeroen Eikenboom, Menno V. Huisman, Frits R. Rosendaal, Johanna G. van der Bom	58
17	[Von Willebrand disease in the Netherlands: the WiN study]. 2014 ·PubMed ·Yvonne Sanders, (unknown), Karina Meijer, Jeroen Eikenboom, Johanna G. van der Bom, (unknown), (unknown), Marjon H. Cnossen, Evelien P. Mauser‐Bunschoten, Frank W.G. Leebeek	4
18	STXBP1 promotes Weibel-Palade body exocytosis through its interaction with the Rab27A effector Slp4-a 2014 ·Blood ·(unknown), Ambrosius P. Snijders, Nicola Hellen, Sarah Weckhuysen, (unknown), Jeroen Eikenboom, Karine M. Valentijn, Mar Fernandez‐Borja, Berten Ceulemans, Peter De Jonghe, Jan Voorberg, Matthew J. Hannah, Tom Carter, Ruben Bierings	43
19	VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease 2013 ·Blood ·Jeroen Eikenboom, Augusto B. Federici, Richard Dirven, Giancarlo Castaman, Francesco Rodeghiero, Ulrich Budde, Reinhard Schneppenheim, Javier Batlle, Maria Teresa Canciani, Jenny Goudemand, I. R. Peake, Anne Goodeve, (unknown)	84
20	The Value of Family History as a Risk Indicator for Venous Thrombosis 2009 ·Archives of Internal Medicine ·Irene D. Bezemer, F.J.M. van der Meer, Jeroen Eikenboom, Frits R. Rosendaal, Carine J.M. Doggen	210

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact